Pharmaceutical

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.

May 25, 2024 - 04:00
ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success
The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.
Read the original article

Tags:

Previous Article

First made-in-Singapore antibody-drug conjugate EBC-129 progresses to phase 1B d...

Next Article

ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

‘Are we better off with the information?’: Experts spar over the benefits of liquid biopsy to catch cancer

‘Are we better off with the information?’: Experts spar...

May 5, 2023

Listen: How Long Island became the ‘eugenics capital of the world’

Listen: How Long Island became the ‘eugenics capital of...

Aug 15, 2023

Plus Therapeutics and PPS expand partnership for cGMP drug production

Plus Therapeutics and PPS expand partnership for cGMP d...

May 2, 2023